Pharmaceuticals, Biotechnology and Life Sciences
MONTREAL & BOCA RATON, Fla.–(BUSINESS WIRE)–Knight Therapeutics Inc. (TSX: GUD) (“Knight”) and TherapeuticsMD, Inc. (NASDAQ: TXMD) (“TherapeuticsMD”) announced today that…
NEW YORK–(BUSINESS WIRE)–$BMY–Bristol-Myers Squibb Company (NYSE:BMY) (“Bristol-Myers Squibb”) announced today the extension of the expiration date of the offers to…
SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the…
SAN DIEGO–(BUSINESS WIRE)–ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to…
– Total Revenue of $271.7 Million, Cabozantinib Franchise Revenue of $191.8 Million – – GAAP Diluted EPS of $0.31, Non-GAAP…
— MARIO-1 Enrollment Completion Expected in 2019 and Data Presentation Expected in 2020 — — MARIO-3 Enrollment Completion and Data…
– Product revenues of $950 million, a 21% increase compared to Q3 2018 – – Continued progression of pipeline of…
Event scheduled for 8:00 a.m. ET Thursday, October 31, 2019 LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host…
Ubiquigent and LEO Pharma A/S have entered into an option agreement granting LEO Pharma access to two novel compounds, which comes after an earlier agreement between the parties entered into as part of LEO Pharma Open Innovation, without disclosing financial terms.
Company Also Receives CE Mark for the VASCADE MVP for Multi-Site Vessel Closure Following Electrophysiology Procedures SANTA CLARA, Calif.–(BUSINESS WIRE)–Cardiva…